Halal Pharmaceuticals Manufacturing in 2025: Navigating Compliance, Capturing New Markets, and Powering Innovation. Explore how this sector is set to transform healthcare and global supply chains over the next five years.

Executive Summary: Key Trends and Market Drivers
Global Market Size, Growth Rate, and 2025–2030 Forecasts
Regulatory Landscape: Halal Certification and Compliance Standards
Technological Innovations in Halal Pharmaceutical Manufacturing
Major Players and Strategic Partnerships (e.g., duopharma.com.my, halalpharma.com)
Supply Chain Management and Traceability Solutions
Consumer Demand, Awareness, and Regional Market Dynamics
Investment, M&A Activity, and Funding Trends
Challenges: Raw Material Sourcing, Quality Assurance, and Cross-Border Trade
Future Outlook: Opportunities, Risks, and Strategic Recommendations
Sources & References

Executive Summary: Key Trends and Market Drivers

The halal pharmaceuticals manufacturing sector is experiencing robust growth in 2025, driven by rising global demand for Shariah-compliant medicines, expanding Muslim populations, and increasing regulatory clarity. The global Muslim population is projected to reach nearly 2 billion by 2025, intensifying the need for pharmaceuticals that adhere to halal standards—free from prohibited substances such as pork derivatives and alcohol, and produced according to Islamic law. This demographic trend is a primary market driver, particularly in Southeast Asia, the Middle East, and parts of Africa.

Key industry players are responding with significant investments in halal-certified production facilities and supply chains. For example, Duopharma Biotech, headquartered in Malaysia, has expanded its portfolio of halal-certified medicines and is actively collaborating with regional health authorities to set benchmarks for halal pharmaceutical standards. Similarly, Chemical Company of Malaysia Berhad (CCM) continues to be a pioneer in halal pharmaceutical manufacturing, leveraging its expertise to meet both domestic and international demand.

Regulatory developments are also shaping the sector. The Malaysian government, through the Department of Islamic Development Malaysia (JAKIM), has strengthened its halal certification processes, and similar frameworks are being adopted in Indonesia and the Gulf Cooperation Council (GCC) countries. The Organization of Islamic Cooperation (OIC) and the Standards and Metrology Institute for Islamic Countries (SMIIC) are working towards harmonizing halal pharmaceutical standards, which is expected to facilitate cross-border trade and reduce compliance complexity for manufacturers.

Technological innovation is another key trend. Companies are investing in advanced traceability systems and blockchain to ensure transparency in sourcing and production, addressing consumer concerns about contamination and authenticity. For instance, Duopharma Biotech has implemented digital tracking for its supply chain, enhancing consumer trust and regulatory compliance.

Looking ahead, the outlook for halal pharmaceuticals manufacturing remains positive. The sector is expected to see continued double-digit growth rates in core markets, with increasing participation from multinational pharmaceutical companies seeking halal certification for their products. Strategic partnerships, R&D in alternative ingredients, and the expansion of halal-certified logistics networks are anticipated to further accelerate market development through 2025 and beyond.

Global Market Size, Growth Rate, and 2025–2030 Forecasts

The global halal pharmaceuticals manufacturing sector is experiencing robust growth, driven by increasing demand from Muslim-majority countries and a rising awareness of halal-certified products among broader consumer bases. As of 2025, the market is estimated to be valued at approximately USD 100 billion, with projections indicating a compound annual growth rate (CAGR) of 6–8% through 2030. This expansion is underpinned by demographic trends, regulatory developments, and the strategic entry of major pharmaceutical companies into halal-compliant production.

Key players in the industry, such as CCM Berhad (Chemical Company of Malaysia Berhad), have established themselves as pioneers in halal pharmaceutical manufacturing, being among the first to receive halal certification for a wide range of products. Duopharma Biotech, another Malaysian leader, has significantly expanded its halal-certified portfolio and actively collaborates with regulatory bodies to set industry standards. In Indonesia, Kimia Farma is a state-owned enterprise that has integrated halal compliance into its manufacturing processes, catering to the world’s largest Muslim population.

The sector’s growth is further supported by the increasing involvement of multinational pharmaceutical companies. For example, Sanofi has established halal-compliant production lines in select facilities to serve Southeast Asian and Middle Eastern markets. Similarly, GSK and Novartis have explored partnerships and product adaptations to meet halal requirements, reflecting a broader industry trend toward inclusivity and compliance with religious standards.

Regulatory frameworks are evolving rapidly, with countries such as Malaysia and Indonesia implementing mandatory halal certification for pharmaceuticals by 2025 and beyond. The Department of Islamic Development Malaysia (JAKIM) and Indonesia’s Halal Product Assurance Agency (BPJPH) are at the forefront of these efforts, providing clear guidelines and certification pathways for manufacturers. This regulatory clarity is expected to further accelerate market growth and attract new entrants.

Looking ahead to 2030, the halal pharmaceuticals manufacturing market is poised for continued expansion, driven by rising healthcare expenditures in Muslim-majority countries, increasing consumer trust in certified products, and ongoing innovation in formulation and supply chain transparency. The sector’s outlook remains positive, with leading companies investing in R&D and certification processes to capture a larger share of this dynamic and increasingly globalized market.

Regulatory Landscape: Halal Certification and Compliance Standards

The regulatory landscape for halal pharmaceuticals manufacturing is evolving rapidly in 2025, driven by increasing global demand for halal-certified medicines and heightened scrutiny from both Muslim-majority and non-Muslim-majority countries. Halal certification in pharmaceuticals requires that products are free from ingredients derived from prohibited sources (such as porcine or alcohol-based substances) and that manufacturing processes prevent cross-contamination, in accordance with Islamic law. The sector is witnessing a convergence of national and international standards, with regulatory authorities and industry bodies working to harmonize requirements and streamline certification processes.

Malaysia remains a global leader in halal pharmaceutical regulation, with its National Pharmaceutical Regulatory Agency (NPRA) and the Department of Islamic Development Malaysia (JAKIM) setting comprehensive guidelines for halal medicines. The Malaysian Standard MS2424:2019, which outlines the general requirements for halal pharmaceuticals, is increasingly referenced by other countries seeking to establish or update their own frameworks. In 2025, Malaysia continues to strengthen its position by collaborating with international partners and promoting mutual recognition of halal certificates, aiming to facilitate cross-border trade and reduce duplication of audits for manufacturers (Pharmaniaga Berhad).

Indonesia, home to the world’s largest Muslim population, has implemented the Halal Product Assurance Law, which mandates halal certification for all pharmaceutical products sold domestically. The Indonesian Ulema Council (MUI) and the Halal Product Assurance Organizing Agency (BPJPH) are responsible for certification and oversight. In 2025, Indonesia is intensifying enforcement, requiring both local and imported pharmaceuticals to comply, and is working with manufacturers to ensure a smooth transition, especially for complex biologics and vaccines (Kimia Farma).

The Gulf Cooperation Council (GCC) countries, including Saudi Arabia and the United Arab Emirates, are also advancing their halal pharmaceutical regulations. The Saudi Food and Drug Authority (SFDA) has issued specific guidelines for halal pharmaceuticals, and the UAE is actively promoting its own halal certification scheme, aiming to become a regional hub for halal medicines. These efforts are supported by local manufacturers such as SPIMACO and Julphar, who are investing in compliance and certification to access both domestic and export markets.

Looking ahead, the outlook for halal pharmaceutical manufacturing is shaped by ongoing standardization efforts, digitalization of certification processes, and increased collaboration between regulatory bodies. The Organization of Islamic Cooperation (OIC) and the Standards and Metrology Institute for Islamic Countries (SMIIC) are working to develop unified halal pharmaceutical standards, which could further facilitate international trade and boost industry growth. As more multinational pharmaceutical companies seek halal certification to tap into the expanding global Muslim market, the regulatory landscape is expected to become more harmonized, transparent, and innovation-friendly over the next few years.

Technological Innovations in Halal Pharmaceutical Manufacturing

The halal pharmaceutical manufacturing sector is undergoing significant technological transformation as it adapts to the growing global demand for halal-certified medicines and health products. In 2025, the industry is characterized by the integration of advanced manufacturing technologies, digital traceability systems, and innovative formulation techniques to ensure compliance with halal standards while maintaining product efficacy and safety.

One of the most notable technological advancements is the adoption of blockchain and digital traceability platforms. These systems enable manufacturers to track the entire supply chain, from sourcing of raw materials to final product distribution, ensuring transparency and preventing cross-contamination with non-halal substances. Companies such as Duopharma Biotech, a leading Malaysian halal pharmaceutical manufacturer, have invested in digital solutions to enhance traceability and support halal integrity throughout their operations.

Another area of innovation is the development of alternative excipients and active pharmaceutical ingredients (APIs) that comply with halal requirements. Traditional excipients like gelatin, often derived from porcine sources, are being replaced with plant-based or synthetic alternatives. CCM Berhad (Chemical Company of Malaysia Berhad), for example, has focused on research and development to create halal-certified formulations, utilizing non-animal derived ingredients and ensuring all processing aids meet halal criteria.

Automation and Industry 4.0 technologies are also being increasingly implemented in halal pharmaceutical manufacturing facilities. Robotics, artificial intelligence, and real-time monitoring systems are used to minimize human error, reduce contamination risks, and optimize production efficiency. These technologies support the stringent requirements of halal certification bodies, such as the Department of Islamic Development Malaysia (JAKIM), by providing detailed records and process controls.

Looking ahead, the outlook for technological innovation in halal pharmaceuticals remains robust. The sector is expected to see further integration of artificial intelligence for predictive quality control, expansion of digital certification platforms, and increased collaboration between manufacturers and certification authorities. Companies like Sime Darby are exploring partnerships and investments in biotechnology to expand their halal product portfolios and enhance manufacturing capabilities.

As the global Muslim population continues to grow and awareness of halal pharmaceuticals increases, technological innovation will be central to meeting regulatory requirements and consumer expectations. The next few years are likely to witness accelerated adoption of digital and biotechnological solutions, positioning halal pharmaceutical manufacturers at the forefront of both compliance and competitiveness.

Major Players and Strategic Partnerships (e.g., duopharma.com.my, halalpharma.com)

The halal pharmaceuticals manufacturing sector is witnessing significant growth and transformation in 2025, driven by increasing global demand for Shariah-compliant medicines and supplements. Key industry players are expanding their production capacities, investing in research and development, and forging strategic partnerships to strengthen their market positions and ensure compliance with stringent halal standards.

One of the most prominent companies in this space is Duopharma Biotech Berhad, headquartered in Malaysia. As a pioneer in halal-certified pharmaceuticals, Duopharma has consistently expanded its product portfolio to include a wide range of prescription and over-the-counter medicines, vitamins, and health supplements. The company has established collaborations with local and international partners to enhance its research capabilities and distribution networks, aiming to serve both Muslim-majority and non-Muslim markets seeking ethical and high-quality products. In 2024 and 2025, Duopharma has continued to invest in advanced manufacturing facilities and has announced new joint ventures to accelerate the development of innovative halal medicines.

Another notable player is Halal Pharma, which specializes in the development and distribution of halal-certified pharmaceutical ingredients and finished products. The company has positioned itself as a key supplier to both manufacturers and healthcare providers seeking to ensure full compliance with halal requirements throughout the supply chain. Halal Pharma’s strategic alliances with raw material suppliers and contract manufacturers have enabled it to maintain rigorous quality assurance processes and expand its reach into emerging markets in Southeast Asia, the Middle East, and Africa.

In addition to these leaders, other manufacturers such as CCM Berhad (Chemical Company of Malaysia Berhad) are also making significant strides in halal pharmaceuticals. CCM Berhad has a long-standing reputation for producing halal-certified healthcare and personal care products, and in recent years, it has intensified its focus on pharmaceutical manufacturing, leveraging its expertise in compliance and certification to capture a larger share of the global halal market.

Strategic partnerships are a defining trend in 2025, with companies collaborating to share technology, streamline certification processes, and access new markets. These alliances often involve cooperation with regulatory bodies, such as national halal certification authorities, to ensure that products meet the highest standards of safety and religious compliance. As the halal pharmaceuticals sector continues to grow, major players are expected to further consolidate their positions through mergers, acquisitions, and cross-border partnerships, setting the stage for robust expansion in the coming years.

Supply Chain Management and Traceability Solutions

The supply chain management and traceability of halal pharmaceuticals are undergoing significant transformation in 2025, driven by increasing global demand for halal-certified medicines and heightened regulatory scrutiny. As Muslim populations grow and awareness of halal compliance expands beyond food into healthcare, pharmaceutical manufacturers are investing in robust systems to ensure the integrity of their supply chains from raw material sourcing to finished product distribution.

A key challenge in halal pharmaceutical manufacturing is the assurance that all ingredients, excipients, and processing aids comply with halal standards throughout the supply chain. This requires rigorous segregation, documentation, and verification processes. Leading manufacturers such as CCM Berhad (Chemical Company of Malaysia Berhad), a pioneer in halal pharmaceuticals, have implemented end-to-end traceability systems that track materials from suppliers through production and distribution. These systems are designed to prevent cross-contamination with non-halal substances and to provide transparent audit trails for certification bodies and regulators.

Digitalization is playing a pivotal role in enhancing traceability. In 2025, companies are increasingly adopting blockchain and Internet of Things (IoT) technologies to create immutable records of product journeys. For example, Duopharma Biotech, another major Malaysian halal pharmaceutical producer, has invested in digital platforms that enable real-time monitoring of supply chain nodes, ensuring compliance with halal requirements at every stage. These platforms facilitate rapid response to any non-compliance incidents and support efficient recall management if necessary.

Collaboration with certification bodies is also intensifying. Organizations such as the Department of Islamic Development Malaysia (JAKIM) are working closely with manufacturers to standardize traceability protocols and integrate halal certification data into digital supply chain management systems. This partnership is crucial for maintaining consumer trust and meeting the stringent requirements of importing countries in the Middle East, Southeast Asia, and beyond.

Looking ahead, the outlook for halal pharmaceutical supply chain management is marked by continued technological innovation and regulatory harmonization. The expansion of halal pharmaceutical standards by international bodies, such as the Organisation of Islamic Cooperation (OIC), is expected to drive further adoption of advanced traceability solutions. As a result, manufacturers are likely to increase investment in supply chain transparency tools, positioning themselves to capture a larger share of the global halal pharmaceutical market, which is projected to grow steadily over the next few years.

Consumer Demand, Awareness, and Regional Market Dynamics

The global halal pharmaceuticals sector is experiencing a marked surge in consumer demand, driven by rising awareness among Muslim populations and a growing preference for products that align with religious and ethical values. As of 2025, the worldwide Muslim population is estimated to exceed 1.9 billion, with significant concentrations in Southeast Asia, the Middle East, South Asia, and parts of Africa. This demographic shift is directly influencing the pharmaceutical industry, as consumers increasingly seek assurance that medicines, supplements, and vaccines are free from non-halal ingredients such as porcine derivatives, alcohol, and non-compliant gelatin.

In Southeast Asia, Malaysia remains a pioneer in halal pharmaceutical manufacturing, with a robust regulatory framework and a dedicated halal certification process overseen by Jabatan Kemajuan Islam Malaysia (JAKIM). Malaysian pharmaceutical companies such as Duopharma Biotech Berhad have expanded their halal-certified product lines, responding to both domestic and export market demand. Indonesia, home to the world’s largest Muslim population, has also implemented mandatory halal certification for pharmaceuticals, with the Halal Product Assurance Agency (BPJPH) playing a central role in enforcement and public education.

The Middle East, particularly the Gulf Cooperation Council (GCC) countries, is witnessing increased investment in halal pharmaceutical manufacturing. Governments and private sector players are collaborating to establish local production facilities and reduce reliance on imports. For example, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is actively involved in developing halal-compliant medicines, leveraging the region’s strategic position as a trade hub for the wider Islamic world.

In Europe, the United Kingdom and Germany have seen a rise in demand for halal pharmaceuticals, particularly among their sizable Muslim communities. Companies such as Renapharma are exploring halal certification to tap into this growing market segment. Meanwhile, in South Asia, Bangladesh’s Incepta Pharmaceuticals and Pakistan’s Getz Pharma are expanding their halal-certified offerings, targeting both local and export markets.

Looking ahead, the outlook for halal pharmaceuticals manufacturing is robust. Regulatory harmonization efforts, such as those led by the Organisation of Islamic Cooperation (OIC), aim to streamline certification and facilitate cross-border trade. As consumer awareness continues to rise, especially among younger, urban populations, demand for transparent labeling and traceable supply chains is expected to intensify. This trend is likely to drive further innovation and investment in halal-compliant pharmaceutical production across key regions in the coming years.

Investment, M&A Activity, and Funding Trends

The halal pharmaceuticals manufacturing sector is experiencing a notable surge in investment, mergers and acquisitions (M&A), and funding activity as global demand for Shariah-compliant medicines continues to rise in 2025. This momentum is driven by the expanding Muslim population, increasing awareness of halal-certified healthcare products, and supportive regulatory frameworks in key markets such as Southeast Asia, the Middle East, and parts of Europe.

Major pharmaceutical companies and contract manufacturers are actively investing in halal-certified production facilities and research capabilities. For instance, Duopharma Biotech Berhad, a leading Malaysian pharmaceutical manufacturer, has consistently expanded its halal-certified product portfolio and invested in advanced manufacturing lines to meet both domestic and export demand. The company’s commitment to halal compliance has positioned it as a preferred partner for multinational firms seeking to penetrate the halal pharmaceuticals market.

In Indonesia, the world’s largest Muslim-majority country, Kimia Farma has accelerated its investment in halal pharmaceutical production, leveraging government incentives and the country’s mandatory halal certification law for medicines. The company is also exploring joint ventures and strategic alliances to enhance its R&D and distribution capabilities, reflecting a broader trend of cross-border collaboration in the sector.

M&A activity is intensifying as both regional and global players seek to consolidate their positions and access new markets. Notably, CCM Berhad (Chemical Company of Malaysia Berhad) has pursued acquisitions and partnerships to expand its halal pharmaceutical offerings, while also investing in compliance infrastructure to maintain certification standards. These moves are indicative of a wider industry pattern, where companies are acquiring smaller halal-certified manufacturers or forming alliances to accelerate market entry and innovation.

Funding trends in 2025 show increased interest from both private equity and government-backed investment funds, particularly in Southeast Asia and the Gulf Cooperation Council (GCC) countries. Governments in Malaysia, Indonesia, and the UAE are providing grants, tax incentives, and regulatory support to encourage halal pharmaceutical manufacturing, recognizing its potential for export growth and healthcare self-sufficiency. For example, Malaysia’s Halal Industry Development Corporation, under the purview of Ministry of Investment, Trade and Industry Malaysia, continues to facilitate investment and international partnerships in the sector.

Looking ahead, the outlook for investment and M&A in halal pharmaceuticals manufacturing remains robust. The sector is expected to see further consolidation, increased venture capital activity, and the entry of new players—both from within the pharmaceutical industry and adjacent sectors such as biotechnology and nutraceuticals. As regulatory harmonization progresses and consumer demand grows, halal pharmaceuticals manufacturing is poised for sustained expansion and innovation through 2025 and beyond.

Challenges: Raw Material Sourcing, Quality Assurance, and Cross-Border Trade

The halal pharmaceuticals manufacturing sector faces a complex landscape of challenges in 2025, particularly in the areas of raw material sourcing, quality assurance, and cross-border trade. As global demand for halal-certified medicines continues to rise, manufacturers are under increasing pressure to ensure that every component of their products—from active pharmaceutical ingredients (APIs) to excipients and packaging—complies with stringent halal standards.

One of the primary challenges is the sourcing of raw materials. Many conventional pharmaceutical ingredients are derived from animal sources or may be processed using alcohol or other non-halal substances. For example, gelatin, commonly used in capsule production, is often sourced from porcine or non-halal bovine origins. Leading halal pharmaceutical manufacturers such as CCM Berhad (Chemical Company of Malaysia Berhad) and Duopharma Biotech have invested in developing and sourcing halal-certified alternatives, but the global supply chain for such materials remains limited and fragmented. This scarcity can lead to higher costs and longer lead times, especially as more countries and consumers demand full traceability and certification.

Quality assurance is another significant hurdle. Halal certification is not a one-time process; it requires ongoing compliance with both Islamic law and international pharmaceutical standards such as Good Manufacturing Practice (GMP). Organizations like Halal Certification Europe and the Department of Islamic Development Malaysia (JAKIM) play a crucial role in setting and auditing these standards. However, the lack of harmonized global halal standards can create confusion and additional compliance burdens for manufacturers operating in multiple markets. For instance, a product certified as halal in Malaysia may not automatically be recognized as such in the Middle East or Europe, necessitating multiple certifications and audits.

Cross-border trade further complicates the landscape. Regulatory requirements for halal pharmaceuticals differ widely between countries, affecting everything from labeling to import documentation. Companies like CCM Berhad and Duopharma Biotech have had to navigate these complexities to export their products to markets such as Indonesia, the Gulf Cooperation Council (GCC) states, and beyond. The lack of mutual recognition agreements between halal certifying bodies can result in delays and increased costs, impeding the efficient movement of goods.

Looking ahead, the sector is expected to see increased collaboration between manufacturers, certifying bodies, and regulators to address these challenges. Initiatives aimed at standardizing halal certification and improving supply chain transparency are likely to gain momentum, but significant hurdles remain. The ability of the industry to overcome these obstacles will be critical to meeting the growing global demand for halal pharmaceuticals in the coming years.

Future Outlook: Opportunities, Risks, and Strategic Recommendations

The future of halal pharmaceuticals manufacturing is poised for significant growth and transformation in 2025 and the coming years, driven by rising global demand, regulatory advancements, and increasing consumer awareness. The global Muslim population, projected to reach nearly 2.2 billion by 2030, continues to fuel demand for halal-certified medicines, especially in Southeast Asia, the Middle East, and parts of Africa. This demographic trend, combined with heightened scrutiny over ingredients and manufacturing processes, is prompting both established pharmaceutical giants and specialized manufacturers to invest in halal-compliant production lines.

Key industry players such as CCM Berhad (now under Duopharma Biotech), Malaysia’s leading halal pharmaceutical manufacturer, have set benchmarks by obtaining halal certification for a wide range of products. Their ongoing expansion and R&D investments signal confidence in the sector’s long-term prospects. Similarly, Simpor Pharma in Brunei and Chemical Company of Malaysia are scaling up halal-certified production, targeting both domestic and export markets.

Opportunities abound as regulatory frameworks mature. The Organization of Islamic Cooperation (OIC) and national bodies such as Malaysia’s Department of Islamic Development Malaysia (JAKIM) are working to harmonize halal standards, which could streamline international trade and reduce compliance complexity. The expansion of halal certification to cover not only finished products but also excipients, packaging, and logistics is expected to create new business avenues for suppliers and contract manufacturers.

However, risks remain. The lack of universally accepted halal pharmaceutical standards can lead to market fragmentation and consumer confusion. Manufacturers face challenges in sourcing halal-compliant raw materials, especially for complex biologics and specialty drugs. Additionally, the cost of certification and ongoing compliance may deter smaller firms from entering the market. There is also the risk of “halal-washing,” where products are misleadingly labeled as halal without rigorous verification, potentially undermining consumer trust and regulatory credibility.

Strategic recommendations for stakeholders include investing in robust supply chain traceability, engaging proactively with certifying bodies, and fostering partnerships with local and international halal authorities. Companies should prioritize transparent communication about their halal compliance processes and leverage digital technologies for certification management. As the sector evolves, collaboration between industry leaders such as Duopharma Biotech, regulatory agencies, and research institutions will be crucial to address technical challenges and build consumer confidence in halal pharmaceuticals worldwide.

Sources & References

THE HALAL PHARMACEUTICAL INDUSTRY

Watch this video on YouTube.

Halal Pharmaceuticals Manufacturing 2025–2030: Accelerating Global Growth & Innovation

ByQuinn Parker